(Q33853512)

29 July 2017

1 reference

title

Miscellaneous treatments: thalidomide, potassium iodide, levamisole, clofazimine, colchicine, and D-penicillamine (English)

1 reference

29 July 2017

0 references

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

1 reference

1 reference

Sanchez MR

1

1 reference

29 July 2017

1 January 2000

1 reference

29 July 2017

Clinics in Dermatology

1 reference

29 July 2017

18

1 reference

29 July 2017

1

1 reference

29 July 2017

131-145

1 reference

The treatment of lepra reaction in lepromatous leprosy. Fifteen years' experience with thalidomide

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

The Influence of Thalidomide on the Clinical and Immunologic Manifestation of Erythema Nodosum Leprosum

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

The effect of thalidomide on experimental tumors and metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Thalidomide for the treatment of chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Thalidomide therapy. An open trial

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Thalidomide: rationale for renewed use in immunological disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Cellular immune effects of thalidomide in actinic prurigo

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Recalcitrant pyoderma gangrenosum: treatment with thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Treatment of cutaneous and pulmonary sarcoidosis with thalidomide.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Behçet disease and the emergence of thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Treatment of Behçet's disease with thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Thalidomide in Weber-Christian disease

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Thalidomide for recalcitrant discoid lesions in a patient with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Thalidomide Therapy for Inflammatory Dermatoses

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Treatment of discoid lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

TNFalpha and response of treatment-resistant adult-onset Still's disease to thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Crossover study of thalidomide vs placebo in Jessner's lymphocytic infiltration of the skin

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Sequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Thalidomide in actinic prurigo

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Polymorphous light eruption: Treatment with thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Actinic prurigo (Hutchinson's summer prurigo)

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Thalidomide in the treatment of actinic prurigo

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Pyoderma gangrenosum associated with Behçet's disease: treatment with thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

[Langerhans histiocytosis in adults: cutaneous and mucous lesion regression after treatment with thalidomide].

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Successful treatment of adult's Langerhans cell histiocytosis with thalidomide. Report of two cases and literature review

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Thalidomide for distressing night sweats in advanced malignant disease

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Development of polyneuropathy during thalidomide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Erythroderma due to thalidomide: report of two cases

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Old and new therapies for sporotrichosis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Sporotrichosis in the metropolitan area of Cusco, Peru, and in its region

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Treatment of cutaneous sporotrichosis with one daily dose of potassium iodide

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Potassium iodide in erythema nodosum and other erythematous dermatoses

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Potassium iodide in the treatment of erythema nodosum and nodular vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Treatment of erythema nodosum and nodular vasculitis with potassium iodide

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Potassium iodide in the treatment of disseminated granuloma annulare

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Treatment of granuloma annulare with potassium iodide

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Pyoderma gangrenosum treated successfully with potassium iodide

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Treatment of pyoderma gangrenosum

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Cutaneous small-vessel vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Atypical Neutrophilic Dermatosis on the Upper Extremity Affected by Postmastectomy Lymphedema: Report of 2 Cases

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Sweet's syndrome: a report on the use of potassium iodide

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

1 reference

7 January 2021

Acute febrile neutrophilic dermatosis (Sweet's syndrome)

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Successful therapy of refractory erythema nodosum associated with Crohn's disease using potassium iodide

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Treatment of acute febrile neutrophilic dermatosis (Sweet's Syndrome) with potassium iodide

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Iododerma: an unusual side effect of iodide ingestion

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Vegetating iododerma with underlying systemic diseases: report of three cases

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Triggering of bullous pemphigoid by iodine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Adjuvant therapy for melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

The role of adjuvant therapy in melanoma management

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Levamisole treatment in steroid-sensitive and steroid-resistant nephrotic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Levamisole and immune response phenomena in cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Oriental sore. A look at trends in and approaches to the treatment of leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Treatment of mucocutaneous herpes simplex infections

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Levamisole in patients with recurrent herpes infection

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Levamisole plus indomethacin in the treatment of herpes simplex

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Pemphigus vulgaris. A study of six cases treated with levamisole and prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Treatment of Behcet's syndrome with levamisole.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Cutaneous sarcoidosis: prognosis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Levamisole therapy in atopic dermatitis: randomized double-blind evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

A Double-Blind, Controlled Trial of Levamisole in the Treatment of Recurrent Herpes Labialis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Verrucae treated by levamisole

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Treatment of multiple viral warts with levamisole

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Dramatic response to levamisole and low-dose prednisolone in 23 patients with oral lichen planus: a 6-year prospective follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Effect of prolonged treatment with levamisole on vitiligo with limited and slow-spreading disease

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Clinical response to levamisole in thirty-nine patients with erythema multiforme. An open prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Clofazimine in dermatology

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Treatment of pyoderma gangrenosum with clofazimine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Erythema elevatum diutinum

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Further Study of the Use olf Clolaziinine in Discoid Lupus Erytheniatosus

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Clofazimine for Residual Nodulocystic Acne Lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Successful treatment of a patient with cutaneous malacoplakia with clofazimine and trimethoprim-sulfamethoxazole

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Clinical trial with clofazimine for treating erythema dyschromicum perstans. Evaluation of cell-mediated immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Involvement of cell adhesion and activation molecules in the pathogenesis of erythema dyschromicum perstans (ashy dermatitis). The effect of clofazimine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Apparent exacerbation of vitiligo syndrome in a patient with pulmonary Mycobacterium avium complex disease who received clofazimine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Clofazimine in the Treatment of Pyoderma Gangrenosum

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Pyoderma gangrenosum treated with clofazimine. Report of three cases

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Malignant pyoderma: a clinical variant of pyoderma gangrenosum

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

["Granulomatous slack skin"--cutaneous elastolytic lymphoma]

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

New drugs for dermatologic diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Treatment of pustular psoriasis with clofazimine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Skin pigmentation from clofazimine therapy in leprosy patients: a reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Familial Mediterranean fever

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Colchicine: 1998 update.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Colchicine for epidermolysis bullosa acquisita

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Epidermolysis bullosa acquisita--successful treatment with colchicine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Successful treatment of chronic bullous dermatosis of childhood with colchicine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Colchicine as a novel therapeutic agent in chronic bullous dermatosis of childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Treatment of linear IgA bullous dermatosis of childhood with colchicine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Effect of colchicine in the subcorneal pustular dermatosis type of IgA pemphigus

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Practical Treatment Recommendations for Pharmacotherapy of Behcetʼs Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Behçet's disease. Report of twenty-five patients from the United States with prominent mucocutaneous involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Colchicine in dermatology

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Colchicine treatment in a case of pachydermoperiostosis with acroosteolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Therapeutic value of colchicine in the treatment of patients with psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Delayed pressure urticaria, objective evaluation of a variable disease using a dermographometer and assessment of treatment using colchicine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Acne conglobata: treatment with isotretinoin, colchicine, and cyclosporin as compared with surgical intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Bullous hemorrhagic primary systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Amyloid goiter and arthritides after kidney transplantation in a patient with systemic amyloidosis and Muckle-Wells syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

The normocomplementemic urticarial vasculitis syndrome‐report of a case and response to colchicine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Erythema elevatum diutinum--a case successfully treated with colchicine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Colchicine. New uses of an old, old drug

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Colchicine in generalized pustular psoriasis: clinical response and antibody-dependent cytotoxicity by monocytes and neutrophils

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Treatment of systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Treatment of primary anetoderma with colchicine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Wilson's disease before and after 5 years of treatment with D-penicillamine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Treatment with D-penicillamine improves dopamine D2-receptor binding and T2-signal intensity in de novo Wilson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Wilson disease: clinical presentation, treatment, and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Use of penicillamine in children with small lead burdens

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Outcome of second line therapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

The long-term use of D-penicillamine for treating rheumatoid arthritis: is continuous therapy necessary?

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Treatment of childhood linear morphea with D-penicillamine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Outcome measurement in scleroderma clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Penicillamine in systemic sclerosis: a reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Management of systemic sclerosis: the art and science

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Treatment of systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

D-penicillamine in the treatment of localized scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

Long-term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: a comparison using life-table methods

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

The effect of continuing penicillamine and gold treatment on the course of penicillamine and gold nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900103-0

7 January 2021

10.1016/S0738-081X(99)00103-0

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10701095